Overview

A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate

Status:
Completed

Trial end date:
2015-07-01

Target enrollment:

Participant gender:

Summary

This study will evaluate immune response following administration of zoster vaccine in subjects with rheumatoid arthritis who are receiving background methotrexate and initiate 5 mg twice daily of tofacitinib or placebo for tofacitinib 2 to 3 weeks following vaccination.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Methotrexate
Polystyrene sulfonic acid
Tofacitinib
Vaccines